Abstract: A particulate form of dithiocarbamate-metal complex and at least one blood protein. The particulate form is obtained by a process having a sequential or simultaneous addition of individual components, resulting in their self-assembling. The aqueous dispersion of the particulate form is suitable for parenteral, oral and topical administration and for therapy and visualization of cancer.

Abstract: Small molecule agonists of the pregnane X receptor (PXR), compositions and methods are disclosed for treating or preventing gut barrier dysfunction, an illness associated with gut barrier dysfunction, toxic or inflammatory injury to intestines, or leaky intestinal (gut) syndrome in a subject.

Abstract: A complex particle form of dithiocarbamate-metal compound and at least one ligand, that is a polymer or a detergent is disclosed. The complex particle form is obtained by a process having a sequential or simultaneous addition of individual components, resulting in their self-assembling. The dry form or aqueous dispersion of the complex particle form is suitable for medicinal per-oral, topical and parenteral administration and for therapy and imaging of cancer.

Abstract: A particulate form of dithiocarbamate-metal complex and at least one blood protein. The particulate form is obtained by a process having a sequential or simultaneous addition of individual components, resulting in their self-assembling. The aqueous dispersion of the particulate form is suitable for parenteral, oral and topical administration and for therapy and visualization of cancer.

Abstract: The method for measuring of quick changes of low surface conductivity of dielectrics under electromagnetic interference of line voltage is based on a comparison measurement on a voltage divider and synchronization of measuring pulses with periodic sinusoidal course of interference when voltage with pre-set parameters of square pulse is brought to the tested dielectric surface and potential is sampled in the voltage divider consisting of the measured dielectric surface and a resistor with preselected resistivity in certain time intervals both before application of the measuring pulse and immediately before its end, and then based on a difference between the values measured using a differential amplifier, the value corresponding to that measured without effect of electromagnetic interference 60 Hz is derived and the result is the possibility to measure quick changes of low surface conductivity of dielectric surface.

Abstract: Method for predicting sensitivity of a patient suffering from cancer to DNA methylation inhibitor therapy uses in vitro in cancer cells taken from the patient. Cells are compared with parent type cells for expression of bromodomain containing genes, of other listed genes, and/or of bromodomain containing proteins. Mutations involving the amino acid sequence of bromodomain containing genes and/or mutations involving non-synonymous change in amino acid sequence of other genes may be examined. The half maximal inhibitory concentration (IC50) of inhibitors of DNA methyltransferase, histone acetyltransferase, histone methyltransferase, histone deacetylases, and/or histone demethylases are determined. Increase in (IC50) signifies cross-resistance. The half maximal inhibitory concentration (IC50) of a selective BET bromodomain inhibitor is also determined, wherein decrease in the (IC50) signifies sensitivity.

Abstract: Compounds of Formula I and a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a mixture of optical isomers thereof, as well as compositions which include such compounds and therapeutic methods that utilize such compounds and/or compositions.

Abstract: Compounds of Formula I and a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a mixture of optical isomers thereof, as well as compositions which include such compounds and therapeutic methods that utilize such compounds and/or compositions.

Abstract: A method for determining the sensitivity and/or resistance of a patient suffering from a cancer disease to Aurora kinase inhibitor therapy, which comprises determining in vitro in the cancer cells or body fluids taken from the patient the expression of at least one gene selected from a particular group and/or determining in vitro in the cancer cells or body fluids taken from the patient the level of at least one protein selected from a particular group.